



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/22/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

Droxidopa oral NORTHERA™ (droxidopa) oral

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/22/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

Droxidopa oral NORTHERA™ (droxidopa) oral

Criteria:

- **Criteria for initial therapy:** Generic droxidopa or Northera (droxidopa) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with a Neurologist, Nephrologist, or Cardiologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of symptomatic neurogenic orthostatic hypotension (NOH) caused by **ONE** of the following conditions:
 - a. Parkinson's disease
 - b. Multiple system atrophy
 - c. Pure autonomic failure
 - d. Dopamine beta-hydroxylase deficiency
 - e. Non-diabetic neuropathy
 4. Orthostatic hypotension is documented as after 5-minutes of supine rest and within 2-5 minutes upon standing or head-up tilt on a tilt table **ONE** of the following:
 - a. A decrease of at least 20 millimeters of mercury (mmHg) in systolic blood pressure (SBP)
 - b. A decrease of at least 10 mmHg decrease in diastolic blood pressure (DBP)
 5. Individual has persistent and consistent symptoms of orthostatic dizziness, lightheadedness, or feelings of about to black out
 6. Non-pharmacologic measures have been maximized:
 - a. Non-pharmacologic factors include:
 - i. Intake of fluid and salt has been liberalized or maximized, where appropriate
 - ii. Uses fitted elastic/compression stockings or abdominal binder, unless contraindicated
 - iii. Head of the bed has been elevated
 - iv. Individual instructed on how to change position from supine to standing in gradual stages
 7. A comprehensive medication review has been performed to either reduce or discontinue agents that contribute or cause orthostatic hypotension, if clinically safe to do so
 8. Individual has failure (at least a 30-day trial), contraindication per FDA label, or intolerance to simultaneous use of **fludrocortisone AND midodrine**
 9. There are no significant interacting drugs

Initial approval duration: 1 month, renewal requires documentation of reduction in orthostatic symptoms **and** an increase in blood pressure for approval



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/22/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

Droxidopa oral NORTHERA™ (droxidopa) oral

- **Criteria for continuation of coverage (renewal request):** Generic droxidopa or Northera (droxidopa) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with a Neurologist, Nephrologist, or Cardiologist
 2. Individual's condition responded while on therapy
 - a. Response is defined as:
 - i. There is a sustained reduction in dizziness, lightheadedness, feeling faint, or feeling like the patient may black out **and** an increase 10 SBP within 3 min of standing
 3. Individual has been adherent with the medication and all non-pharmacologic measures as deemed appropriate for the individual patient
 4. Individual has not developed any significant adverse drug effects that may exclude continued use
 - a. Significant adverse effect such as:
 - i. Persistent supine hypertension
 - ii. Neuroleptic Malignant Syndrome (NMS)-like reaction with hyperpyrexia and confusion
 - iii. Hypersensitivity reactions such as anaphylaxis, angioedema, bronchospasms, urticaria, and rash
 5. There are no significant interacting drugs

Renewal duration: 6 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:
1. **Off-Label Use of Non-cancer Medications**
 2. **Off-Label Use of Cancer Medications**

Description:

Generic droxidopa or brand Northera (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure [Parkinson's disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF)], dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. The effectiveness of droxidopa beyond 2 weeks of treatment has not been established, continued effectiveness of droxidopa should be assessed periodically.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/22/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

Droxidopa oral

NORTHERA™ (droxidopa) oral

Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, which is extensively distributed throughout the body. It is believed to exert its effects through norepinephrine and not through the parent molecule. Norepinephrine increases blood pressure by inducing peripheral arterial and venous vasoconstriction.

Use of droxidopa is associated with a risk of increased blood pressure while lying down (supine hypertension), individuals must sleep with their head and upper body elevated. In addition, it may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure.

Orthostatic hypotension:

- Orthostatic hypotension may be categorized as neurogenic or non-neurogenic in origin
- Non-neurogenic causes include disorders that result in cardiac impairment, reduced intravascular volume and electrolyte loss, venous pooling/vasodilation, and iatrogenic from use of numerous medications
 - Age related orthostatic hypotension is considered a non-neurogenic cause of orthostatic hypotension
- Neurogenic causes include Parkinson's disease (PD), pure autonomic failure (PAF), and multiple system atrophy (MSA)
- Orthostatic hypotension is a physical finding and is defined as a documented decrease of ≥ 20 millimeters of mercury (mmHg) in systolic blood pressure (SBP) or a ≥ 10 mmHg decrease in diastolic blood pressure (DBP) within 3 minutes upon standing or a head-up tilt on a tilt table
- Symptoms of orthostatic hypotension include dizziness, lightheadedness, blurred vision, fatigue and fainting when a person stands
- There are known predisposing factors that cause or contribute to orthostatic hypotension such as dehydration, deconditioning, poor nutrition, aging, and others, as well as numerous drugs such as diuretics, antihypertensive agents, anti-anginal agents, antidepressants, alpha-blockers, and others
- Management of orthostatic hypotension involves liberalizing and maximizing fluid and sodium intake (where appropriate), elevation of head of the bed, a comprehensive review of medications used to reduce the doses or discontinue agents that contribute to orthostatic hypotension (if safe to do so), patient education on how to change position from supine to standing in gradual stages, and use of fitted elastic stockings
- Pharmacologic agents used to treat orthostatic hypotension include fludrocortisone and midodrine
- Midodrine is the only other FDA-approved medication for symptomatic orthostatic hypotension
 - Midodrine is a direct acting agonist for peripheral alpha-1 adrenoreceptors
 - It is a pro-drug that is activated to desglymidodrine, the active receptor agonist



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/22/2015
LAST REVIEW DATE: 2/17/2022
LAST CRITERIA REVISION DATE: 2/17/2022
ARCHIVE DATE:

Droxidopa oral NORTHERA™ (droxidopa) oral

- Desglymidodrine is 15 times more potent than the parent compound and is primarily responsible for the therapeutic effect
 - The pressor effect is due to both arterial and venous constriction
 - The dose should be titrated from 2.5 mg to 10 mg three times a day
- Fludrocortisone is commonly used off-label to treat orthostatic hypotension
 - Fludrocortisone, is a synthetic mineralocorticoid, is considered agent of first choice for orthostatic hypotension and is used in individuals who are not able to increase plasma volume effectively with liberalized fluid and salt intake
 - It has a long duration of action and is well-tolerated by most individuals
 - Fludrocortisone increases blood volume and enhances the sensitivity of blood vessels to circulating catecholamines
 - Other potential actions include enhancing norepinephrine release from sympathetic neurons and increasing vascular fluid content
 - Treatment is initiated with a 0.1 mg tablet and can be increased to 1 mg daily although little benefit is obtained by increasing beyond 0.5 mg daily
- Other off-label treatments that are less commonly used include ephedrine, desmopressin, dihydroergotamine, erythropoietin, indomethacin, octreotide, pyridostigmine, and yohimbine

Resources:

Northera (droxidopa) product information, revised by Lundbeck Pharmaceuticals, LLC. 12-2021. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed January 10, 2022.

Droxidopa product information, revised by Lupin Pharmaceuticals, Inc. 03-2021. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed January 10, 2022.

Palma JA, Kaufmann H. Mechanisms, causes, and evaluation of orthostatic hypotension. In: UpToDate, Aminoff MJ, Goddeau RP (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Topic last updated January 07, 2022. Accessed January 11, 2022.

Palma JA, Kaufmann H. Treatment of orthostatic and postprandial hypotension. In: UpToDate, Aminoff MJ, Kowey P, Goddeau RP (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Topic last updated July 06, 2021. Accessed January 11, 2022.